EASL 2012 Report – Europe bears high costs of chronic liver diseases and high mortality in cirrhosis
by Bruce Sylvester – Two studies presented at EASL suggest the real human and economic costs of liver disease across Europe.
by Bruce Sylvester – Two studies presented at EASL suggest the real human and economic costs of liver disease across Europe.
C. difficile is a bacterium that is common in the environment. According to the Center for Disease Control and Prevention, approximately 337,000 cases of CDI are reported each… read more.
by Bruce Sylvester – Researchers report that combination ABT-450 with ritonavir (ABT-450/r, Abbott) plus ABT-333 plus ribavirin (RBV) is both well tolerated and led to high sustained virological… read more.
Safety results were similar between groups. Data presented at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tocilizumab monotherapy is more effective than… read more.
by Bruce Sylvester – Researchers report that, in the last quarter of the 20th century, changes in smoking behaviors have led to a significant drop in lung cancer… read more.
by Bruce Sylvester – Opioid treatment offers relief and improved quality of life to patients with advanced chronic obstructive pulmonary disease (COPD) and shortness of breath,
by Bruce Sylvester – A research paper published in ‘Tobacco Control’ by the British Medical Journal (BMJ) shows that tobacco control policies implemented in Ireland between 1998 and… read more.
by Bruce Sylvester – Diabetes adds to hearing loss with age among women, if it is not well controlled with medication,
by Bruce Sylvester – Combination metformin and rosiglitazone is more effective than metformin monotherapy in youth with recent-onset type 2 diabetes,
Emerging uses of EMA Approved Drugs – by Gary Finnegan – Several new medicines have been approved by the European Medicines Agency after recent meetings of its Committee… read more.
Emerging uses of EMA Approved Drugs – by Gary Finnegan – The EMA has launched a public consultation on the classification of advanced therapies.
Emerging uses of EMA Approved Drugs – by Gary Finnegan – The European Medicines Agency is emerging from a turbulent spell which has seen the departure of one… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.